-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, SU6gpTZMJEy2D+rA/GYR7Z3UA46HnwZEhySa5pyNv68T9GfZdD21ffjFy4/48TWg u7ZHPsvhelpm9kpXzLI3jw== 0000950123-10-098832.txt : 20101101 0000950123-10-098832.hdr.sgml : 20101101 20101101164018 ACCESSION NUMBER: 0000950123-10-098832 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100930 FILED AS OF DATE: 20101101 DATE AS OF CHANGE: 20101101 EFFECTIVENESS DATE: 20101101 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BB BIOTECH AG CENTRAL INDEX KEY: 0000924223 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-06964 FILM NUMBER: 101155352 BUSINESS ADDRESS: STREET 1: VODERGASSE 3 STREET 2: SWITZERLAND CITY: SCHAFFHAUSEN STATE: V8 ZIP: CH-8300 BUSINESS PHONE: 411724 59 59 MAIL ADDRESS: STREET 1: VODERGASSE 3 STREET 2: SWITZERLAND CITY: SCHAFFHAUSEN STATE: V8 ZIP: CH-8300 13F-HR 1 w80320de13fvhr.txt FORM 13F-HR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 13F Form 13F COVER PAGE Report for Calendar Year or Quarter Ended: September 30, 2010 Check here if Amendment [ ]; Amendment Number: __________ This Amendment (Check only one.): [ ] is a restatement. [ ] adds new holdings entries. Institutional Investment Manager Filing this Report: Name: BB Biotech AG Address: Vordergasse 3 Schaffhausen Switzerland CH-8200 Form 13F File Number: 28-6964 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Pascal Schmucki Title: SIGNING AUTHORITY Phone: 41 (44) 267 67 00 Signature, Place, and Date of Signing: /s/ Pascal Schmucki ----------------------------------------- Schaffhausen, Switzerland, November 1, 2010 Report Type (Check only one.): [X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [ ] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [ ] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) 1 Form 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 3 Form 13F Information Table Entry Total: 16 Form 13F Information Table Value Total: $888,808 (thousands) List of Other Included Managers: Provide a numbered list of the name(s) and Form 13F file number(s) of all institutional investment managers with respect to which this report is filed, other than the manager filing this report. No. Form 13F File Number Name - --- -------------------- ---- 1 28-11193 Biotech Focus N.V. 2 28-11191 Biotech Invest N.V. 3 28-11189 Biotech Target N.V. 2 BB BIOTECH AG FORM 13F INFORMATION TABLE
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8 -------------- -------- --------- -------- ------------------ ---------- -------- --------------------- VOTING AUTHORITY TITLE OF VALUE SHS OR SH/ PUT/ INVESTMENT OTHER --------------------- NAME OF ISSUER CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE -------------- -------- --------- -------- --------- --- ---- ---------- -------- --------- ------ ---- Affymetrix Inc COM 00826T108 9,120 2,000,000 SH DEFINED 1 2,000,000 NONE NONE Alexion Pharmaceuticals Inc COM 015351109 20,917 325,000 SH DEFINED 2 325,000 NONE NONE Amgen Inc COM 031162100 27,555 500,000 SH DEFINED 1 500,000 NONE NONE Arena Pharmaceuticals Inc COM 040047102 3,156 2,010,080 SH DEFINED 3 2,010,080 NONE NONE Biomarin Pharmaceutical Inc COM 09061G101 21,514 962,583 SH DEFINED 2 962,583 NONE NONE Celgene Corp COM 151020104 251,435 4,364,439 SH DEFINED 2 4,364,439 NONE NONE Elan Plc ADR 284131208 8,625 1,500,000 SH DEFINED 2 1,500,000 NONE NONE Genzyme Corp COM 372917104 21,379 302,000 SH DEFINED 1 302,000 NONE NONE Gilead Sciences Inc COM 375558103 199,942 5,614,768 SH DEFINED 1 5,614,768 NONE NONE Halozyme Therapeutics Inc COM 40637H109 20,467 2,654,582 SH DEFINED 3 2,654,582 NONE NONE Idenix Pharmaceuticals Inc COM 45166R204 2,622 845,693 SH DEFINED 3 845,693 NONE NONE Immunogen COM 45253H101 24,608 3,924,776 SH DEFINED 3 3,924,776 NONE NONE Incyte Corp COM 45337C102 47,623 2,978,300 SH DEFINED 3 2,978,300 NONE NONE Micromet Inc COM 59509C105 37,613 5,597,101 SH DEFINED 3 5,597,101 NONE NONE Optimer Pharmaceuticals Inc COM 68401H104 18,780 2,048,003 SH DEFINED 3 2,048,003 NONE NONE Vertex Pharmaceuticals Inc COM 92532F100 173,452 5,017,408 SH DEFINED 3 5,017,408 NONE NONE
3 -----END PRIVACY-ENHANCED MESSAGE-----